Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial.

Trial Profile

Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Cisplatin; Erlotinib
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 May 2008 Status change from in progress to discontiuned, as reported on clinicaltrials.gov
    • 06 Feb 2008 Status changed from recruiting to in progress.
    • 11 Apr 2007 Status changed from initiated to recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top